Neuralink CEO Elon Musk recently described his company's brain-chip technologies, aimed at overcoming paralysis and blindness, as "Jesus-level technologies." Speaking virtually at the Samson International Smart Mobility Summit in Tel Aviv on May 18, 2026, Musk highlighted the profound impact these advancements could have on human capability. The statement comes as Neuralink continues to expand its human trials for both motor control and vision restoration.
Neuralink's PRIME Study, which began human implantation in January 2024, has seen significant progress in assisting individuals with paralysis. As of January 2026, 21 patients worldwide have received the N1 implant, enabling them to control digital devices using thought alone. Early participants, such as Noland Arbaugh, have demonstrated the ability to play video games, navigate computers, and even engage in complex software use, showcasing a restoration of digital independence.
The company is also making strides with its Blindsight implant, designed to restore vision by directly stimulating the visual cortex. Blindsight received FDA Breakthrough Device Designation in September 2024, expediting its development. Human trials for Blindsight are anticipated to commence by late 2025 or early 2026, following successful long-term testing in non-human primates. Initial vision restoration is expected to be low-resolution, akin to early video game graphics, with potential for future enhancements.
Musk elaborated on his "Jesus-level technologies" comment, stating, "Restoring control of people who are tetraplegics and restoring sight I think are pretty big deals." He further clarified that these were "miracles in the scientific sense," emphasizing the transformative potential of Neuralink's work. The entrepreneur also suggested the technology could eventually lead to "superhuman vision."
Neuralink plans to initiate high-volume production of its brain-computer interface devices and transition to a largely automated surgical procedure in 2026. The company has secured substantial funding, including a $650 million Series E round in 2025, to support its ambitious goals. While the immediate focus remains on individuals with severe medical needs, Neuralink's president and co-founder DJ Seo has indicated aspirations to implant chips in healthy individuals by 2030, though some researchers urge caution regarding the long-term implications and feasibility of high-resolution visual restoration.
